Oncology

March 11th 2020 marked the day that the World Health Organization (WHO) escalated the coronavirus SARS-CoV-2 (COVID-19) outbreak from a public health…

In accordance with ‘taking care’ of the cancer patient, the management of non-small cell lung cancer (NSCLC) is currently carried…

Lung cancer has a devastating global impact. Claiming over 2 million lives in 2018, it is the world’s leading cause of cancer-related morbidity…

This meeting took place on 28th September 2019, as part of the Ferring-organised Meet-The-Expert symposium at the European Society of Medical Oncology. Main topic is discussion of new treatment modalities in the management of high-risk, non-muscle invasive bladder cancer.

Cancer immunotherapy has been profiled as one of the major breakthroughs of the decade and will probably remain a paramount biomedical landmark in…

With a sustained number of new drugs or combination drugs entering standard of care this year, molecular testing should be…

Despite the impressive advances that have been made in cancer diagnosis and therapy, there still exist groups of patients who are not responding to standard anticancer treatments…

Epithelial myoepithelial carcinoma (EMC) was initially described by Donath et al…